Melanoma has been at the forefront of precision oncology and immunotherapy for over a decade. The discovery that approximately 50% of cutaneous melanomas harbor BRAF V600E/K mutations led to the development of BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib), while the success of ipilimumab and nivolumab established immunotherapy as a curative-intent treatment for advanced disease, with long-term survival exceeding 20% at 10 years in some trials.
Current trials investigate anti-PD-1/LAG-3 combinations (relatlimab/nivolumab, already approved), triple checkpoint blockade, personalized neoantigen vaccines combined with anti-PD-1, tumor-infiltrating lymphocyte (TIL) therapy (lifileucel, FDA approved), and BRAF/MEK inhibitor combinations with immunotherapy for BRAF-mutated disease. Adjuvant trials aim to prevent recurrence in resected high-risk Stage III disease.
BRAF mutation status is required for enrollment in targeted therapy trials. Uveal, mucosal, and acral melanoma subtypes have distinct biology and are studied separately from cutaneous melanoma.
Frequently Asked Questions — cutaneous melanoma Clinical Trials
How many clinical trials are currently recruiting for cutaneous melanoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for cutaneous melanoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for cutaneous melanoma?
cutaneous melanoma research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a cutaneous melanoma clinical trial?
Eligibility criteria for cutaneous melanoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
OncoResponse, Inc. 1 trial
Medicenna Therapeutics, Inc. 1 trial
Melanoma Institute Australia 1 trial
University of California, San Francisco 1 trial
Recruiting Clinical Trials
NCT06090266 Phase 1, Phase 2
Recruiting
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Sponsor
OncoResponse, Inc.
View Trial → NCT05086692 Phase 1, Phase 2
Recruiting
A Beta-only IL-2 ImmunoTherapY Study
Location
United States, Austr...
Sponsor
Medicenna Therapeutics, Inc.
View Trial → NCT06999980 Phase 2
Recruiting
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Sponsor
Melanoma Institute Australia
View Trial → NCT07148245
Recruiting
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
Sponsor
University of California, San ...
View Trial → ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: July 2026 ·
Data Methodology